/
Other
Fatigue
29
Pipeline Programs↗
50
Active Trials↗
26
Companies Involved↗
Fatigue is an emerging landscape with 29 programs across 26 companies. The most active players are Biogen, AstraZeneca. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical22
Phase 34
Approved
No programs
Analysis
Modality Breakdown
96%
Small molecule
27 of 28 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.
Analysis
Trial Status
184
clinical trials
Completed87 · 47%
Unknown status24 · 13%
Recruiting22 · 12%
Not yet recruiting20 · 11%
Terminated13 · 7%
Withdrawn9 · 5%
Other9 · 5%
Clinical Trials
Trial Activity
184 trials
Sleep, Mental Fatigue, and Performance: Psychobiological Insights for Optimizing Learning in Physiotherapy and Psychology Students
Recruiting·—·N/A·NCT07644611·30 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300 mg Capsules in Reducing Chemotherapy-Induced Fatigue in Patients With Metastatic Triple-Negative Breast Cancer Receiving Standard Chemotherapy
Recruiting·—·Phase 3·NCT07669467·250 enrolled
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.
Recruiting·—·Phase 3·NCT07669454·250 enrolled
Page 1 of 13
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)